Immunotherapy of cancer by antisense inhibition of Ii protein, and immunoregulator of antigen selection by MHC class II molecules

Current Opinion in Molecular Therapeutics

Volumn 6, Issue 2, 2004, Pages 160-165

  Xu, Minzhen ^a   Lu, Xueqing ^a   Kallinteris, Nikoletta L ^a   Wang, Yu ^b   Wu, Shuzhen ^a   Von Hofe, Eric ^a   Gulfo, Joseph V ^a   Humphreys, Robert E ^a   Hillman, Gilda G ^b  

^a Antigen Express Inc   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer vaccine; Ii antisense; Immunotherapy; Major histocompatibility complex class II; T helper cell

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; B LYMPHOCYTE ANTIGEN; HLA ANTIGEN CLASS 2; TUMOR ANTIGEN;

ANIMAL; ANTIGEN PRESENTING CELL; ARTICLE; CLINICAL TRIAL; GENE; GENE THERAPY; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; INVARIANT CHAIN; METHODOLOGY; MOUSE; NEOPLASM; PATHOLOGY;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; ANTIGENS, NEOPLASM; CLINICAL TRIALS; GENE THERAPY; GENES, MHC CLASS II; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOTHERAPY; MICE; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE;

EID: 7944228149     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Karttunen JT, Lehner PJ, Gupta SS, Hewitt EW, Cresswell P: Distinct functions and cooperative interaction of the subunits of the transporter associated with antigen processing (TAP). Proc Natl Acad Sci USA (2001) 98(13):7431-7436.
2. Bryant PW, Lennon-Dumenil AM, Fiebiger E, Lagaudriere-Gesbert C, Ploegh HL: Proteolysis and antigen presentation by MHC class II molecules. Adv Immunol (2002) 80:71-114.
3. Kessler BM, Glas R, Ploegh HL: MHC class I antigen processing regulated by cytosolic proteolysis-short cuts that alter peptide generation. Mol Immunol (2002) 39(3-4):171-179.
4. Ridge JP, Di Rosa F, Matzinger P: A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature (1998) 393(6684):474-478.
5. Germain RN: Ligand-dependent regulation of T cell development and activation. Immunol Res (2003) 27(2-3):277-286.
6. Dorfman JR, Stefanova II, Yasutomo K, Germain RN: Response to 'Class II essential for CD4 survival'. Nat Immunol (2001) 2(2):136-137.
7. Xu M, Capraro GA, Daibata M, Reyes VE, Humphreys RE: Cathepsin B cleavage and release of invariant chain from MHC class II molecules follow a staged pattern. Mol Immunol (1994) 31 (10):723-731.
8. Daibata M, Xu M, Humphreys RE, Reyes VE: More efficient peptide binding to MHC class II molecules during cathepsin B digestion of Ii than after Ii release. Mol Immunol (1994) 31(4):255-260.
9. Spiro RC, Sairenji T, Humphreys RE: Identification of hairy cell leukemia subset defining p35 as the human homologue of Ii. Leukemia Res (1984) 8(1):55-62.
10. Jiang Z, Xu M, Savas L, LeClair P, Banner BF: Invariant chain expression in colon neoplasms. Virchows Arch (1999) 435(1):32-36.
11. Georgiannos SN, Renaut A, Goode AW, Sheaff M: The immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major histocompatibility complex in cell-mediated immune mechanisms, and their association with prognostic indicators. Surgery (2003) 134(5):827-834.
12. Casares N, Arribillaga L, Sarobe P, Dotor J, Lopez-Diaz De Cerio A, Melero I, Prieto J, Borras-Cuesta F, Lasarte JJ: CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-γ-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol(2003) 171(11):5931-5939.
13. Chil A, Sikorski M, Bobek M, Jakiel G, Marcinkiewicz J: Alterations in the expression of selected MHC antigens in premalignant lesions and squamous carcinomas of the uterine cervix. Acta Obstet Gynecol Scand (2003) 82(12):1146-1152.
14. Schroers R, Shen L, Rollins L, Xiao Z, Sonderstrup G, Slawin K, Huang XF, Chen SY: Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen. Clin Cancer Res (2003) 9(9):3260-3271.
15. Antony PA, Restifo NP: Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy? J Immunother (2002) 25(3):202-206.
16. Thornton AM, Shevach EM: Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. Immunology (2000) 164(1):183-190.
17. Weiner HL: Induction and mechanism of action of transforming growth factor-β-secreting Th3 regulatory cells. Immunol Rev (2001) 182:207-214.
18. Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, Kaiser LR, June CH: Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol (2002) 168(9):4272-4276.
19. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, Dellemijn TA, Antony PA, Spiess PJ, Palmer DC, Heimann DM et al: Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 198(4):569-580.
20. Krug A, Veeraswamy R, Pekosz A, Kanagawa O, Unanue ER, Colonna M, Cella M: Interferon-producing cells fail to induce proliferation of naive T cells but can promote expansion and T helper 1 differentiation of antigen-experienced unpolarized T cells. J Exp Med (2003) 197(7):899-906.
21. Chamoto K, Kosaka A, Tsuji T, Matsuzaki J, Sato T, Takeshima T, Iwakabe K, Togashi Y, Koda T, Nishimura T: Critical role of the Th1/Tc1 circuit for the generation of tumor-specific CTL during tumor eradication in vivo by Th1-cell therapy. Cancer Sci (2003) 94(10):924-928.
22. Ho WY, Yee C, Greenberg PD: Adoptive therapy with CD8+ T cells: It may get by with a little help from its friends. J Clin Invest (2002) 110(10):1415-1417.
23. Clements VK, Baskar S, Armstrong TD, Ostrand-Rosenberg S: Invariant chain alters the malignant phenotype of MHC class II+ tumor cells. J Immunol (1992) 149(7):2391-2396.
24. Baskar S, Glimcher L, Nabavi N, Jones RT, Ostrand-Rosenberg S: Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med (1995) 181(2):619-629.
25. Armstrong TD, Clements VK, Martin BK, Ting JP, Ostrand-Rosenberg S: Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc Natl Acad Sci USA (1997) 94(13):6886-6891.
26. Qi L, Ostrand-Rosenberg S: MHC class II presentation of endogenous tumor antigen by cellular vaccines depends on the endocytic pathway but not H2-M. Traffic (2000) 1(2):152-160.
27. Qi L, Rojas JM, Ostrand-Rosenberg S: Tumor cells present MHC class II restricted nuclear and mitochondrial antigens and are the predominant antigen presenting cells in vivo. J Immunol (2000) 165(10):5451-5461.
28. Qiu G, Goodchild J, Humphreys RE, Xu M: Cancer immunotherapy by antisense suppression of Ii protein in MHC-class II-positive tumor cells. Cancer Immunol Immunother (1999) 48(9):499-506.
29. Lu X, Kallinteris NL, Li J, Wu S, Li Y, Jiang Z, Hillman GG, Gulfo JV, Humphreys RE, Xu M: Tumor immunotherapy by converting tumor cells to MHC class II-positive, Ii protein-negative phenotype. Cancer Immunol Immunother (2003) 52(10):592-598.
30. Hillman GG, Kallinteris NL, Li J, Wang Y, Lu X, Li Y, Wu S, Wright JL, Slos P, Gulfo JV, Humphreys RE, Xu M: Generating MHC class II+/Ii-phenotype after adenoviral delivery of both an expressible gene for MHC class II inducer and an antisense Ii-RNA construct in tumor cells. Gene Ther (2003) 10(17):1512-1518.
31. Hillman GG, Xu M, Wang Y, Wright JL, Lu X, Kallinteris NL, Tekyi-Mensah S, Thompson TC, Mitchell MS, Forman JD: Radiation improves intratumoral gene therapy for induction of cancer vaccine in murine prostate carcinoma. Hum Gene Ther (2003) 14(8):763-775.
32. Dezso B, Haas GP, Hamzavi F, Kim S, Montecillo EJ, Benson PD, Pontes JE, Maughan RL, Hillman GG: The mechanism of local tumor irradiation combined with interleukin 2 therapy in murine renal carcinoma: Histological evaluation of pulmonary metastases. Clin Cancer Res (1996) 2(9):1543-1552.
33. Zeng M, Cerniglia GJ, Eck SL, Stevens CW: High-efficiency stable gene transfer of adenovirus into mammalian cells using ionizing radiation. Hum Gene Ther (1997) 8(9):1025-1032.
34. Stevens CW, Zeng M, Cerniglia GJ: Ionizing radiation greatly improves gene transfer efficiency in mammalian cells. Hum Gene Ther (1996) 7(14):1727-1734.
35. Thierry AR, Vives E, Richard JP, Prevot P, Martinand-Mari C, Robbins I, Lebleu B: Cellular uptake and intracellular fate of antisense oligonucleotides. Curr Opin Mol Ther (2003) 5(2):133-138.
36. Sazani P, Vacek MM, Kole R: Short-term and long-term modulation of gene expression by antisense therapeutics. Curr Opin Biotechnol (2002) 13(5):468-472.
37. Peakman M, Stevens EJ, Lohmann T, Narendran P, Dromey J, Alexander A, Tomlinson AJ, Trucco M, Gorga JC, Chicz RM: Naturally processed and presented epitopes of the islet cell autoantigen IA-2 eluted from HLA-DR4. J Clin Invest (1999) 104(10):1449-1457.
38. Wolchok JD, Gregor PD, Nordquist LT, Slovin SF, Scher HI: DNA vaccines: An active immunization strategy for prostate cancer. Semin Oncol (2003) 30(5):659-666.
39. Ponsaerts P, Van Tendeloo VF, Berneman ZN: Cancer immunotherapy using RNA-loaded dendritic cells. Clin Exp Immunol (2003) 134(3):378-384.
40. Engleman EG: Dendritic cell-based cancer immunotherapy. Semin Oncol (2003) 30(3 Suppl 8):23-29.